Figure 6. ALG10 knockdown suppressed the activity of TGF-β signaling by reducing TGFBR2 glycosylation. (A and B) The activity of Luc-TCF-1 and Luc-smad was evaluated in HCT-116 and HT-29 cells with or without ALG10 knockdown. (C) The status of TGFBR1/2 glycosylation was detected in HCT-116 and HT-29 cells with or without ALG10 knockdown. (D) The status of TGFBR2 glycosylation and p-smad2 expression were evaluated in HCT-116 cells with or without ALG10 knockdown or Tunicamycin treatment. (E) The nucleus expression of p-smad2 was examined in HCT-116 and HT-29 cells with or without ALG10 knockdown or Tunicamycin treatment. (F) The TGFBR1-TGFBR2 and TGFBR1-p-smad2 interaction was measured in HCT-116 and HT-29 cells with or without ALG10 knockdown. (G) The mRNA expression of FOXD1, SPHK1, CHST1, and EST2 was determined in HCT-116 and HT-29 cells with or without ALG10 knockdown or Tunicamycin treatment. n = 3, **P < 0.01 vs. Control.